Thursday, 29 October 2026 Every NSE & BSE announcement, by company
ALFA Filings Every announcement, straight from the exchange
Earnings Call Transcript

Sat Kartar Life Earnings Call Transcript: Key Takeaways

Sat Kartar Life is pivoting from pure Ayurveda products to an integrated healthcare model, showing strong revenue growth but scaling back prior top-line guidance to prioritize margins.

Guidance and delivery
Management target Revenue 32.5% FY27
Highlights
Revenue growth26.4% YoY growth in H1 FY27 to ₹113.9 Cr.
MarginsImproving; PAT margins expected at 11-12% for FY27.
Demand visibilityStrong demand for fertility, men's wellness, and de-addiction segments.
Management confidenceBalanced, but admits prior top-line guidance was overly aggressive.

Growth

H1 revenue grew 26.4% YoY to ₹113.9 Cr, with EBITDA increasing 47.7% and margins improving 180bps to 12.7%.

Outlook

Targeting 30-35% revenue growth for FY27 and maintains ₹500 Cr revenue target for FY28 with significantly higher margins.

Risks

Management lowered FY27 revenue guidance from ₹300 Cr to ~₹285 Cr; high marketing spend (40%) remains a structural drag.

Source

Earnings Call Transcript filed with NSE, NSE: SATKARTAR. Summary written with AI assistance from the document.

Read the document ↗

Sat Kartar Life Ltd: key numbers

Share price
₹130.35
Market cap
₹205.9 Cr
Revenue (annual)
₹200.7 Cr
Net profit (annual)
₹17.10 Cr
P/E (TTM)
12.0×Sector 46.1×
Promoter holding
63.49%
FII holding
0.77%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

More from Sat Kartar Life Ltd

All →